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Serologic studies for swine infl uenza viruses (SIVs) 
in humans with occupational exposure to swine have 
been reported from the Americas but not from Europe. 
We compared levels of neutralizing antibodies against 3 
infl uenza viruses—pandemic (H1N1) 2009, an avian-like 
enzootic subtype H1N1 SIV, and a 2007–08 seasonal 
subtype H1N1—in 211 persons with swine contact and 
224 matched controls in Luxembourg. Persons whose 
profession involved contact with swine had more neutralizing 
antibodies against SIV and pandemic (H1N1) 2009 virus 
than did the controls. Controls also had antibodies against 
these viruses although exposure to them was unlikely. 
Antibodies against SIV and pandemic (H1N1) 2009 virus 
correlated with each other but not with seasonal subtype 
H1N1 virus. Sequential exposure to variants of seasonal 
infl uenza (H1N1) viruses may have increased chances for 
serologic cross-reactivity with antigenically distinct viruses. 
Further studies are needed to determine the extent to which 
serologic responses correlate with infection.
Pandemic (H1N1) 2009 infl uenza virus resulted from genetic reassortment between at least 2 swine infl uenza 
viruses (SIVs) (1). Hemagglutinin (HA) of this novel 
subtype H1N1 virus is similar to that of classical swine 
infl uenza virus and the triple reassortant subtype H1N1 
viruses that are endemic in swine populations in North 
America. At the time of its detection in humans, pandemic 
(H1N1) 2009 virus had never been detected in swine 
populations anywhere, but it is believed to have circulated 
undetected in regions with little or no surveillance for 
infl uenza viruses in swine. Because this virus has not 
been reported by the European Surveillance Network for 
Infl uenza in Pigs (www.esnip.ugent.be) since the network’s 
inception in 2001, it was most likely absent in swine in 
western Europe. By the end of 2009, pandemic (H1N1) 
2009 virus infection of swine had been reported in Norway 
(2); sporadic cases have been reported in a few other 
European countries (e.g., Germany, Italy, Denmark) (3). 
The swine were probably infected by contact with infected 
humans, whereas transmission from swine to humans has 
not yet been documented. Pandemic (H1N1) 2009 virus 
is the fi rst swine-origin virus that is readily transmitted 
between humans (4).
Human infections with SIVs are rare. During 1958–
2005, only 50 cases of zoonotic infections were reported; 
most were in persons who had contact with swine (5). 
Limited secondary transmission to close contacts has been 
reported but appears to be rare, and to our knowledge, 
sustained human-to-human transmission of enzootic SIVs 
has never been noted (6). Some serologic studies suggest 
that persons who work with swine are at increased risk for 
zoonotic infection with SIVs (7–12).
The predominant subtype H1N1 SIVs in Europe were 
introduced from wild ducks to swine in 1979 and have 
an entirely avian-derived genome (13–15). These viruses 
are designated as avian-like viruses and are antigenically 
distinct from subtype H1N1 SIVs in North America and 
from pandemic (H1N1) 2009 virus. Few cases of human 
infection with these avian-like swine subtype H1N1 viruses 
have been reported; chains of transmission have not been 
found (5,9,15), and no serologic studies have provided 
indirect evidence of transmission of SIVs to humans in 
Europe (15).
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Studies in the United States, United Kingdom, and 
Finland found antibodies against pandemic (H1N1) 2009 
virus in elderly persons (16–18). These antibodies can 
be explained by antigenic evolution of seasonal human 
infl uenza (H1N1) viruses that are derived from the 1918 
pandemic virus (such as the classical swine infl uenza 
[H1N1] virus) but have undergone greater antigenic drift 
than the swine virus (19). Antigenically, the infl uenza 
(H1N1) viruses that circulated among humans before the 
1950s are probably more closely related to the classical 
swine virus and thus to the pandemic (H1N1) 2009 virus 
than to contemporary human subtype H1N1 viruses. We 
investigated whether persons whose professions involve 
contact with swine (swine workers [SWs]) have neutralizing 
antibodies against 3 infl uenza viruses: pandemic (H1N1) 
2009 virus, a European avian-like subtype H1N1 SIV, and 
a 2007–08 seasonal infl uenza subtype H1N1 (seasonal 
infl uenza) virus. 
Methods
Study Population
During July 20–28, 2009, blood was collected from 
211 healthy persons with past or present professional 
contact with swine. All participants gave informed consent 
and completed a questionnaire about the nature of their 
swine contacts (occupation, duration, frequency), infl uenza 
vaccination, and infl uenza infection history. No participant 
reported having been infected with pandemic (H1N1) 2009 
virus. A total of 224 control serum samples were obtained 
from the serum bank of the Laboratoires Reunis, Junglinster, 
Luxembourg. The samples, from the general population of 
Luxembourg, had been submitted in December 2008 for 
routine serologic testing. Because of ethical constraints, 
no further information was gathered from controls. The 
study was approved by the National Ethical Committee for 
Research in Humans.
Virus Neutralization Assay
According to recommended World Health 
Organization protocols (20), serum samples were tested by 
virus neutralization assay against an infl uenza A (H1N1) 
virus strain isolated from a patient in Luxembourg in 
July 2009 (A/Luxembourg/43/2009). Complete genome 
analyses revealed that the sequence was almost identical 
to the prototype vaccine virus (A/California/7/2009) and 
represented a typical North American/European pandemic 
(H1N1) 2009 virus (4). Nucleotide sequences are available 
from GenBank (accession nos. FN423708–15). A/swine/
Belgium/1/98 is representative of the avian-like subtype 
H1N1 SIVs that are enzootic in swine populations of 
western Europe (21). Both viruses have an antigenically 
distinct H1 and ≈72% aa identity in the HA1 region (93% 
and 98% aa identity in neuraminidase [NA] and matrix [M] 
proteins) (22). A representative of the 2007–08 seasonal 
infl uenza virus was included in the assay and had 73% and 
74% identity in HA1 proteins compared with pandemic 
(H1N1) 2009 virus and SIV (A/Luxembourg/572/2008 HA 
gene, accession no. FR716024).
Positive control serum was collected from 5 patients >5 
weeks after recovery from a laboratory-confi rmed infection 
with pandemic (H1N1) 2009 virus and from a previously 
unexposed pig 4 weeks after it had been experimentally 
infected with A/swine/Belgium/1/98 (H1N1) (21). Before 
the assay was conducted, all samples were heated to 
56°C for 30 min to inactivate complement and unspecifi c 
inhibitors. Titers were reported as the reciprocal of the 
highest dilution of serum that completely neutralized virus 
growth. Samples were fi rst screened in duplicate with a 
1:10 dilution. All samples that showed virus neutralization 
in ≥1 well were further titrated in quadruplicate up to a 
dilution of at least 1:320. Control samples positive for both 
viruses were included in all assays.
Statistical Analyses
Geometric mean titers (GMTs) were calculated 
for each person from quadruplicate serum samples. All 
negative samples were given an arbitrary GMT of 5. GMTs 
were compared by using the nonparametric Wilcoxon 
rank-sum test. To examine bivariate risk factors associated 
with antibody prevalence, we dichotomized GMTs of all 
positive samples for different cutoff points (>10 to >80) 
and analyzed them by χ2 test and, for low proportions, by 
z-test. The distribution of antibody levels was checked for 
associations with multiple risk factors by using proportional 
odds modeling (23,24). Statistical analyses were performed 
by using SigmaStat version 3.1 (San Jose, CA, USA) and 
SPSS version 18 (Chicago, IL, USA).
Results
Study Population
Mean age of the 211 SWs was 48.2 years (range 
18–94 years); 67.8% were male (Table 1). Most (84.8%) 
SWs reported having worked daily in close contact with 
swine (distance <1 m, 83%) for >10 years (73.5%). Among 
the SWs, 133 were involved in pig breeding, fattening, or 
general pig farming; 51 were slaughterhouse workers; 12 
were veterinarians; 13 were butchers; and 2 were hunters. 
The 224 controls were matched with SWs by age and sex 
(Table 1).
Antibodies against Pandemic (H1N1) 2009 Virus 
GMTs of antibodies against pandemic (H1N1) 2009 
virus (Table 2) were signifi cantly higher for SWs than for 
controls (p = 0.004). Table 3 shows that 2× more SWs 
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than controls had neutralizing antibodies against pandemic 
(H1N1) 2009 virus for the lowest cutoff value (p = 0.001). 
This ratio slightly increased with rising cutoff values and 
remained signifi cant to a cutoff >160 (Table 3). In all age 
groups, ≈2× more SWs than controls had antibodies against 
pandemic (H1N1) 2009 virus (cutoff >10), except for 
persons >60 years of age (Table 4). For SWs and controls 
>60 years of age, GMTs for pandemic (H1N1) 2009 virus 
were similar (p = 0.897; Table 2). GMTs were signifi cantly 
higher for younger than for older (>60 years) SWs (but 
not controls) (Table 2). Among SWs, antibodies against 
pandemic (H1N1) 2009 virus tended to decrease with 
age for all cutoff values; among controls, the same was 
observed for cutoffs >10 to >40. Thus, younger SWs more 
often had higher levels of antibodies against pandemic 
(H1N1) 2009 virus than did controls and older SWs. The 
difference between SWs and controls disappeared in 
older age groups and was weaker when older and younger 
controls were compared.
Antibodies against SIV 
Similar to fi ndings for pandemic (H1N1) 2009 virus, 
GMTs for SIV were higher among SWs than controls; 
however, the difference was not signifi cant (Table 2; p 
= 0.168). More SWs than controls had positive SIV titers 
regardless of the cutoff (Table 3). These differences were 
signifi cant for cutoffs >20 to >160 and increased with higher 
cutoffs (Table 3). Comparable to fi ndings for pandemic 
(H1N1) 2009 virus, for age groups up to 60 years antibodies 
against SIV were found in 1.2–2× more SWs than controls 
(cutoff >10; Table 4); GMTs were signifi cantly higher 
among SWs than controls in this age group (Table 2; p = 
0.028). Seroprevalences and GMTs were similar for persons 
>60 years of age from each group (Tables 2, 4).
In contrast to fi ndings for pandemic (H1N1) 2009 
virus, the highest proportion of seropositive persons was 
found in older age groups, SWs >50 and controls >60 years 
(Table 4). GMTs were signifi cantly higher among older 
(>60 years) than younger controls (p = <0.001) but differed 
little among SWs (Table 2; p = 0.293).
Thus, antibody titers for SIV were found more often 
and were higher among SWs than controls. In contrast to 
fi ndings for pandemic (H1N1) 2009 virus, titers for SIV 
were found more often and were higher for older than 
younger controls; for SWs, titers were found more often 
among older persons but values were similar.
Antibodies against Pandemic (H1N1) 2009 
Virus and SIV
Among SWs, for all cutoff values seroprevalence 
was higher for SIV than for pandemic (H1N1) 2009 virus. 
The same was found for controls but only for lower titers 
(≥10 and ≥20; Table 3). The differences between antibody 
positivity for each of the 2 viruses increased with age among 
SWs and controls (Table 4). Comparing seroprevalences for 
pandemic (H1N1) 2009 virus to those for SIV, differences 
were signifi cant only for SWs >60 years (p = 0.002). Also, 
signifi cantly more controls of the same age group (>60 
years) had antibodies against SIV (62.2%) than against 
pandemic (H1N1) 2009 virus (6.7%, p<0.001; Table 4). 
The proportion of older (>60 years) SIV-seropositive 
controls (62.2%) differed signifi cantly from the proportion 
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Table 1. Characteristics of persons tested for 3 influenza viruses, 
Luxembourg, 2008–2009*
Characteristic
Swine workers, 
no. (%),† n = 211
Controls, no. 
(%),‡ n = 224
Sex
M 143 (67.8) 151 (67.4)
F 68 (32.2) 73 (32.6)
Age group, y§
18–40 69 (32.7) 80 (35.7)
41–50 59 (28) 58 (25.9)
51–60 39 (18.5) 41 (18.3)
61–94 44 (20.9) 45 (20.1)
Profession
Farmer 133 NA
Slaughterhouse worker 51 NA
Other¶ 27 NA
Years worked with swine
<1 4 (1.9) NA
1–4 26 (12.3) NA
5–10 26 (12.3) NA
>10 155 (73.5) NA
Unknown 0 224
Frequency of swine contact
Rarely 3 (1.4) NA
Monthly 2 (0.9) NA
Weekly 25 (11.8) NA
Daily 179 (84.8) NA
Unknown 2 (0.9) NA
Frequency of close contact (<1 m) with swine
Never 1 (0.5) NA
Rarely 3 (1.4) NA
Occasionally 10 (4.7) NA
Often 22 (10.4) NA
Always 175 (82.9) NA
Self-reported influenza vaccine in past 5 y
No/unsure 155 (73.5) NA
Yes 56 (26.5) NA
Self-reported infection with seasonal influenza
No 145 (68.7) NA
Yes 57 (27.0) NA
Exposure to swine
Only until 1997 26 NA
Only until 2007 59 NA
Until time of collection 152 NA
*NA, not available.
†Sampled in July 2009.
‡Sampled in December 2008.
§Mean (median) age 48.2 (48) years for swine workers, 47.6 (47.2) years 
for controls.
¶Veterinarian, butcher, hunter.
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of younger (<60 years) SIV-seropositive controls (17.3%; 
p<0.001).
Thus, for both groups, more persons had antibodies 
against SIV than against pandemic (H1N1) 2009 virus, and 
differences in positivity decreased with increasing titers. 
Antibodies against SIV were more common among older 
persons, and antibodies against pandemic (H1N1) 2009 
virus were more common among younger persons.
Antibodies against SIV and Pandemic (H1N1) 
2009 Virus
Antibody titers of convalescent-phase serum samples 
from patients with pandemic (H1N1) 2009 virus were 
16× higher for pandemic (H1N1) 2009 virus than for SIV 
(GMTs 226.2 vs. 13.5, respectively), indicating low cross-
reactivity between these viruses. Similarly, in a pig serum 
sample, GMT for SIV (>1,280) was 128× lower than that 
for pandemic (H1N1) infl uenza (8).
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Table 2. Geometric mean titers for 3 influenza viruses in swine workers and controls, Luxembourg, 2008–2009* 
Virus (strain) and participant age, y 
Study sample, % (95% CI) 
p value† Swine workers, n = 211 Controls, n = 224 
Pandemic (H1N1) 2009 (A/Luxembourg/43/2009) 
 All 8.7 (7.5–10) 6.1 (5.6–6.6) 0.004 
 <60 9.2 (7.6–11.1)‡ 6 (5.5–6.7) <0.05
 >60 5.6 (4.5–6.9) 5.4 (4.6–6.4) 0.897 
Avian-like SIV (H1N1) (A/swine/Belgium/1/98) 
 All 10.3 (8.8–12) 7.7 (6.9–8.5) 0.168 
 <60 9.8 (8.1–11.8) 6.4 (5.8–7)§ <0.05
 >60 11.2 (8–15.5) 13.6 (9.9–18.5) 0.170 
Seasonal influenza (H1N1) (A/Luxembourg/572/2008)¶ 
 All 23.2 (20.3–26.4) 13.9 (12.1–15.9) <0.001 
 <60 21.3 (18.3–24.7) 12.4 (10.7–14.4)# <0.001 
 >60 30.6 (22.7–41.1) 20.1 (15.3–28.7) 0.083 
*%, no. persons/total no. persons in age groups with geometric mean titer cutoff >10. SIV, swine influenza virus. 
†p value <0.05 for significance were calculated by using the Wilcoxon rank-sum test. Boldface indicates significance (p<0.05). 
‡p<0.05, compared with swine contacts of the age group >60 y against pandemic (H1N1) 2009 virus. 
§p<0.001, compared with controls of the age group >60 y against avian-like SIV. 
¶Data for 210 swine workers, 221 controls. 
#p = 0.001, compared with controls of the age group >60 y against seasonal influenza (H1N1). 
Table 3. Neutralizing antibody reactivity against 3 influenza viruses in swine workers and controls, Luxembourg, 2008–2009* 
Virus (strain) and cutoff value 
Swine workers,  
no. (%; 95% CI), n = 211 
Controls,
no. (%; 95% CI), n = 224 p value 
Pandemic (H1N1) 2009 (A/Luxembourg/43/2009)
 >10 46 (21.8; 16.8–27.9)† 23 (10.3); 6.9–14.9)‡ 0.001§ 
 >20 37 (17.5; 13–23.2)† 16 (7.1; 4.4–11.3)‡ 0.001§ 
 >40 31 (14.7; 10.6–20.1) 12 (5.4; 3.1–9.1) 0.002§ 
 >80 14 (6.6; 4–10.8) 4 (1.8; 0.7–4.5) 0.02§ 
 >160 6 (2.8; 1.3–6.06) 0 (0; 0–1.2) 0.033¶ 
 >320 5 (2.4; 1–5.4) 0 (0; 0–1.2) 0.061¶
Avian-like SIV (H1N1) (A/swine/Belgium/1/98)
 >10 66 (31.3) 25.4–37.8) 59 (26.3; 21–32.5) 0.289§ 
 >20 57 (27; 21.5–33.4) 38 (17; 12.6–22.4) 0.015§ 
 >40 39 (18.5; 13.8–24.3) 12 (5.4; 3.1–9.1) <0.001§ 
 >80 21 (10; 6.6–14.7) 4 (1.8; 0.7–4.5) <0.001§ 
 >160 9 (4.3; 2.3–7.9) 1 (0.4; 0.1–2.5) 0.019¶ 
 >320 4 (1.9; 0.7–4.8) 1 (0.4; 0.1–2.5) 0.331¶
Seasonal influenza (H1N1) (A/Luxembourg/572/2008)#
 >10 183 (87.1; 83–91.9) 132 (59.7; 53.2–66) <0.001§ 
 >20 125 (59.5; 52.8–65.9) 76 (34.4; 28.4–40.9) <0.001§ 
 >40 61 (29; 23.3–35.5) 39 (17.6; 13.2–23.2) 0.007§ 
 >80 21 (10; 6.6–14.9) 17 (7.7; 4.8–12) 0.500§ 
 >160 14 (6.7; 3.9–11) 7 (3.2; 1.4–6.5) 0.144§ 
 >320 11 (5.2; 2.9–9.2) 4 (1.8; 0.5–4.7) 0.093§ 
*Values are no. persons with antibodies. CI, confidence interval; SIV, swine influenza virus. Boldface indicates significance (p<0.05). 
†p<0.05 when compared with swine workers against avian-like SIV (H1N1) of the same titer cutoff. 
‡p<0.003 when compared with swine workers against avian-like SIV (H1N1) of the same titer cutoff. 
§Ȥ2 test on 2-way table. 
¶z-test. 
#Data for 210 swine workers, 221 controls.
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Among 66 SIV-positive serum samples from SWs, 
only 28 were also positive for pandemic (H1N1) 2009 
virus (GMT cutoff >10). GMTs of at least single positive 
samples correlated signifi cantly with each other (R2 = 
0.5, correlation coeffi cient [CC] = 0.4, p<0.001; Figure, 
panel C); and GMTs for SIV were signifi cantly higher 
than corresponding GMTs for pandemic (H1N1) 2009 
virus (48, 95% CI 38.4–60.1, and 16.3, 95% CI 11.3–22.8, 
respectively; p<0.001). To the contrary, among SIV-
positive controls GMTs for SIV did not correlate with 
GMTs for pandemic (H1N1) 2009 virus (R2<0.01, CC = 
0.322; Figure, panel D).
Among SWs, being SIV positive increased the odds 
of being positive for pandemic (H1N1) 2009 virus by 2.4× 
(odds ratio [OR] 95% CI 1.3–4.3). Among controls, these 
chances were increased by 6× (OR 95% CI 2.9–12.6).
Seasonal Infl uenza Virus Compared with 
Pandemic (H1N1) 2009 Virus and SIV 
GMTs for seasonal infl uenza virus were signifi cantly 
higher among SWs than controls (Table 2), and 
signifi cantly more SWs than controls had antibodies 
against seasonal infl uenza virus, at least for titers ≈10 to 40 
(Table 3). Among all age groups, more SWs than controls 
had antibodies against seasonal infl uenza (Table 4). GMTs 
among controls >60 years of age were signifi cantly higher 
than those among younger controls (Table 2). Signifi cantly 
more SWs and controls had antibodies against seasonal 
infl uenza virus than against pandemic (H1N1) 2009 virus 
and SIV (Table 3).
All SWs with antibodies against pandemic (H1N1) 
2009 virus also had antibodies against seasonal infl uenza 
virus with the following exceptions: 1) GMTs were 
signifi cantly higher for pandemic (H1N1) 2009 virus (50.8, 
95% CI 37.7–68.4) than for seasonal infl uenza viruses 
(31.5, 95% CI 26.6–37.4) (p = 0.001); 2) GMTs of at least 
single positive serum samples did not correlate (R2<0.01, 
CC = 0.231; Figure, panel A); and 3) 17 of 21 samples 
with seasonal infl uenza virus titers >80 were negative for 
pandemic (H1N1) 2009 virus (cutoff <10). No correlation 
was found between GMTs of samples positive for seasonal 
infl uenza virus and SIV (R2<0.01, CC = 0.339; Figure, 
panel B). These results may indicate no substantial cross-
reactivity between antibodies against pandemic (H1N1) 
2009 virus or SIV and at least a recent seasonal infl uenza 
virus.
Risk Factors 
Odds of having antibodies against pandemic (H1N1) 
2009 virus were 2.4× (95% CI 1.4–4.2) to 3.9 (95% CI 1.3–
12) greater for SWs than for controls (cutoffs >10 to >160). 
Odds of having antibodies against SIV were 1.3× (95% CI 
0.8–1.9) to 9.9 (95% CI 0.5–38.9) greater for SWs than for 
controls (cutoffs >10 to >80). Odds of being SIV positive 
were slightly higher for farmers (OR 2.3, 95% CI 1.1–5) 
than for slaughterhouse workers; odds of being positive for 
pandemic (H1N1) 2009 virus were only slightly higher for 
farmers than for slaughterhouse workers (OR 1.2, 95% CI 
0.6–2.5). ORs for being positive for pandemic (H1N1) 2009 
virus and for SIV were slightly higher for male SWs (1.7, 
95% CI 0.8–3.5, and 1.1, 95% CI 0.6–2.3, respectively; 
cutoff >10). Among SWs, 26.5% self-reported receiving >1 
dose of seasonal infl uenza vaccine during the past 5 years; 
among vaccinated SWs, the odds of having antibodies 
against pandemic (H1N1) 2009 virus (OR 1.3, 95% CI 0.6–
2.6) as well as against SIV (OR 1.3, 95% CI 0.7–2.5; cutoff 
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Table 4. Neutralizing antibody reactivity >10 for 3 influenza viruses in swine workers and controls, Luxembourg, 2008–2009* 
Participant
age in 2009, y 
Pandemic (H1N1) 2009 
(A/Luxembourg/43/2009) 
Avian-like SIV (H1N1) 
(A/swine/Belgium/1/98) 
Seasonal influenza (H1N1) 
(A/Luxembourg/572/2008) 
Swine workers Controls Swine workers Controls Swine workers  Controls
<40 22/69 (31.9; 
22.1–43.6)† 
12/80 (15;  
8.8–24.4) 
19/69 (27.5; 
18.4–39.0) 
15/80 (18.8;  
11.7–28.7) 
58/68 (85.3;  
6.9–93.7) 
50/78 (64.1;  
53.5–74.8) 
41–50 10/59 (16.9; 
9.5–28.5) 
5/58 (8.6;  
3.7–18.6) 
11/59 (18.6; 
10.7–30.4) 
8/58 (13.8;  
7.2–24.9) 
46/59 (78;  
67.4–88.6) 
29/57 (50.9;  
37.9–63.9) 
51–60 9/39 (15.3; 
12.7–38.3) 
3/41 (7.3;  
2.5–19.4) 
17/39 (43.6; 
29.3–59.0)‡ 
8/41 (19.5;  
10.2–34.0) 
37/39 (94.9;  
88.0–101.8)§ 
19/41 (46.3;  
31.1–61.6) 
>60 5/44 (8.6;
5.0–24.0)¶ 
3/45 (6.7;  
2.3–17.9)# 
19/44 (43.2; 
29.7–57.8) 
28/45 (62.2;  
47.6–74.9) 
42/44 (95.5;  
89.3–101.6)** 
34/45 (75.6;  
63.0–88.1) 
18–94 (total) 46/211 (21.8;  
16.8–27.9)†† 
23/224 (10.3; 
6.9–14.9)‡‡ 
66/211 (31.3; 
25.4–37.8) 
59/224 (26.3; 
21.0–32.5) 
183/210 (87.1;  
83.0–91.9) 
132/221 (59.7; 
53.2–66.0) 
*Values are no. persons/total no. persons in age groups with antibody reactivity >10 (%; 95% confidence interval). p values <0.05 cutoff for significance 
were calculated by using the Ȥ2 test. SIV, swine influenza virus. 
†p = 0.012, compared with controls of the same age group against pandemic (H1N1) 2009. 
‡p = 0.037, compared with controls of the same age group against avian-like SIV (H1N1). 
§p<0.001, compared with controls of the same age group against seasonal influenza (H1N1). 
¶p = 0.002, compared with swine workers of the same age group against avian-like SIV (H1N1). 
#p<0.001, compared with controls of the same age group against avian-like SIV (H1N1). 
**p<0.05, compared with controls of the same age group against seasonal influenza (H1N1). 
††p<0.05, compared with swine workers against avian-like SIV (H1N1). 
‡‡p<0.001, compared with controls against avian-like SIV (H1N1). 
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>10) were slightly higher than those for unvaccinated SWs. 
Odds of having antibodies against pandemic (H1N1) 2009 
virus were slightly higher for SWs exposed to swine until 
the time of sampling (OR 1.5, 95% CI 0.7–3.3) in 2009 
than for those who had no contact with swine after 2007. 
OR for having antibodies against SIV for SWs with pig 
contact until time of sampling was 0.5 (95% CI 0.2–1.1) 
compared with that for persons who had no contact after 
1997. Thus, no signifi cant associations were found between 
year of exposure and seroprevalence of antibodies against 
either virus.
Discussion
At the time of blood collection from SWs (late 
July 2009), pandemic (H1N1) 2009 had spread to all 
continents, but intensity was still low in Europe, especially 
in Luxembourg and its neighboring countries. The only 
countries in which infection rates increased were the United 
Kingdom, Ireland, and Spain (where sporadic outbreaks 
occurred) (25). In 2009, Luxembourg had an intensive 
active surveillance system for infl uenza-like illnesses. 
Follow-up for all patients with suspected cases included 
patient travel history, RNA extraction, and PCR to detect 
pandemic (H1N1) 2009 virus. All patients with confi rmed 
408 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011
Figure. Geometric mean titers (>10) of antibodies against pandemic (H1N1) 2009 virus, seasonal infl uenza (H1N1) virus, and swine 
infl uenza virus of swine workers (A, B, C) and controls (D). Each symbol represents titer of 1 person; only persons with positive results 
(>10) for at least 1 of the 2 viruses of the panel are shown. Trend lines are shown; R2 values were R2>0.01 for panels A, B, and D and R2 
= 0.5 for panel C.
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disease were monitored until at least early August. Patients 
and their contacts received prompt antiviral drug treatment, 
and home quarantine was recommended. In Luxembourg, 
≈60 cases were reported and confi rmed around the time 
that blood collection from SWs was ending. Until end 
of June 2009, almost all Luxembourg patients were 
epidemiologically unrelated, and the source of infection 
was not determined for one fi fth (26). The fi rst sustained 
transmissions were noted by mid September (J. Mossong, 
pers. comm.). The fi rst cases of pandemic (H1N1) 2009 in 
swine on the European mainland were reported in January 
2010 (3). Nevertheless, the difference in the time of blood 
collection from controls (December 2008) and from SWs 
(July 2009) is a limitation of our study.
The virus neutralization assay used measures 
neutralizing antibodies mainly against HA because 
antibodies were in the assay only during the virus 
entry phase (20). Nevertheless, we cannot exclude that 
residual antibodies against NA and M (93% and 98% aa 
identity between pandemic [H1N1] 2009 virus and SIV, 
respectively) may contribute to neutralization (27).
Because there is no correlate of protection for 
neutralizing antibodies or a defi nition of a positive titer 
measured by virus neutralization assay (28), we analyzed 
titers by using running cutoff values for positivity and 
compared GMTs. This analysis showed signifi cantly 
higher prevalence of neutralizing antibodies against 
pandemic (H1N1) 2009 virus in SWs than in controls, and 
seropositivity decreased with age. Younger (<60 years) 
SWs had higher titers, and 2× more SWs than age-matched 
controls had neutralizing antibodies against pandemic 
(H1N1) 2009.
No evidence indicates that pandemic (H1N1) 2009 
virus was present in swine in Europe in or before July 2009. 
Reactivity with pandemic (H1N1) 2009 virus correlated 
best with antibodies against SIV. Although this correlation 
was highly signifi cant among SWs with relatively high 
titers for SIV, no such correlation was found among 
controls, in whom antibody levels against SIV were low. 
We speculate that the difference between the cohorts may 
refl ect cross-reactive antibodies to another infl uenza virus 
more similar to SIV (with or without a minor contribution 
of antibodies against seasonal infl uenza) in SWs, in contrast 
to low, mainly cross-reacting seasonal infl uenza virus 
antibodies in controls. Serologic cross-reaction between 
SIV and pandemic (H1N1) 2009 virus in pigs was recently 
reported (22). Our results also showed that reactivity with 
pandemic (H1N1) 2009 (or SIV) in either cohort cannot 
be explained by cross-reactivity with a recent seasonal 
infl uenza virus used in this study. Nevertheless, because 
more SWs than controls were exposed to seasonal infl uenza 
virus, we cannot exclude the possibility that antibodies to 
pandemic (H1N1) 2009 virus or to SIV in the SWs may be 
caused by a more complex history of exposure to seasonal 
infl uenza virus of subtype H1 or to subclinical infections 
with pandemic (H1N1) 2009 virus during the fi rst months 
of the pandemic.
Our fi nding of low levels of neutralizing antibodies 
against pandemic (H1N1) 2009 in controls (general 
population) is in agreement with fi ndings of previous 
studies (29). Our fi ndings that titers were less common 
but higher for older controls contrast with reports from 
the United Kingdom and Finland (16,17) but agree with 
fi ndings of 2 studies in China, where elderly persons (>60 
years) had few or no neutralizing antibodies against this 
virus (30,31).
Our study also showed signifi cantly higher prevalence 
of neutralizing antibodies against SIV in SWs than in the 
controls at cutoffs >20 to >160, but differences in GMTs 
were not signifi cant. Similar serologic studies in humans 
in the United States showed markedly elevated antibody 
titers for North American SIVs of subtype H1N1 and 
H1N2 in SWs compared with controls (5,8,10,11,32,33). 
These studies used hemagglutination inhibition instead of 
virus neutralization assays and reported ORs for increased 
serologic responses instead of seroprevalence rates. The 
reported ORs, however, seem to be higher than those in 
our study (8,32,33) and could be partially explained by 
exclusion of persons with swine exposure in the US control 
groups.
Most persons undergo sequential infections with 
multiple antigenic variants of human infl uenza subtype 
H1N1 and H3N2 viruses throughout their lives. Such 
infections strongly increase the odds for serologic cross-
reactions with antigenically distinct H1 viruses, as 
documented in experimental studies with pigs (22), and 
may explain why older persons in the general population 
have higher antibody titers to SIV than their younger 
counterparts. Both older and younger controls are unlikely 
to have been infected with SIV, but older persons have been 
exposed to a wider variety of human seasonal infl uenza 
viruses. This exposure is also refl ected by a signifi cant 
difference in GMTs for recent seasonal infl uenza virus 
in older than younger controls. In Luxembourg, elderly 
persons may have had contact with swine because during 
1920–1947 in Luxembourg, 50%–22% of all households 
kept >5 pigs, but before 1979, there was no apparently 
substantial swine infl uenza activity in this part of Europe 
(14). Apart from antibodies to SIV, a few controls also had 
antibodies to pandemic (H1N1) 2009 virus, but these did 
not correlate with each other, suggesting a different cross-
reactivity pattern than that for SWs. These fi ndings show 
that in the absence of paired serum samples, presence of 
neutralizing antibodies to a given infl uenza virus does 
not necessarily refl ect infection with that virus. Elevated 
antibody titers to SIV in part of the SWs may have resulted 
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from exposure to the virus, but further studies are required 
to determine all possible causes.
In conclusion, titers of antibodies against pandemic 
(H1N1) 2009 virus and against an avian-like subtype H1N1 
infl uenza virus were found more frequently and were 
higher for SWs than for controls. These titers cannot be 
explained by cross-reactivity with antibodies from recent 
seasonal infl uenza viruses. Neutralizing antibodies to both 
subtype H1N1 viruses showed some degree of correlation.
Further studies are needed to determine incidence of 
zoonotic SIV infections and the extent to which serologic 
responses correlate with infection. Neutralizing antibodies 
should confer at least partial protection against infection, 
reducing the risk that the avian-like subtype H1N1 SIV will 
cause major outbreaks of disease in humans.
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